DYRK1A
ENSG00000157540
Target class
Kinase
Chromosome
21
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- DYRK1A
- Gene name
- Dual specificity tyrosine phosphorylation regulated kinase 1A
- Gene symbol
- DYRK1A
- Protein name
- Dual specificity tyrosine-phosphorylation-regulated kinase 1A (EC 2.7.11.23) (EC 2.7.12.1) (Dual specificity YAK1-related kinase) (HP86) (Protein kinase minibrain homolog) (MNBH) (hMNB)
- DYRK1
- DYRK
- MNBH
- Gene biotype
- Protein coding
- Gene family
- Dual-specificity tyrosine-regulated kinase family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 35.25
- Tissue specificity (Gini)
- 0.228
- Tissue specificity (tau)
- 0.456
- KEGG gene identifiers
- hsa:1859
- Reactome pathways
- R-HSA-1538133
- End position
- 37526358
- Start position
- 37365573
- Chromosome
- 21
- Strand
- Forward
- Nucleus . Nucleus speckle .
- Nuclear speckles
- Nucleoplasm
- PubMed 20167603
- PubMed 23415227
- PubMed 25620562
- Tissue specificity (tau)
- 0.456309
- Expression inequality (Gini)
- 0.227585
Expression in transcripts per million
- Uterus
- 35.25
- Cervix - Endocervix
- 31.95
- Thyroid
- 31.88
- Cervix - Ectocervix
- 31.12
- Artery - Tibial
- 30.93
Expression in transcripts per million
- Uterus35.25
- Cervix - Endocervix31.95
- Thyroid31.88
- Cervix - Ectocervix31.12
- Artery - Tibial30.93
- Ovary30.75
- Fallopian Tube30.41
- Brain - Cerebellar Hemisphere28.43
- Bladder27.84
- Testis26.6
- Lung26.2
- Nerve - Tibial26.08
- Spleen24.44
- Vagina24.37
- Esophagus - Muscularis23.94
- Adipose - Subcutaneous23.65
- Cells - EBV-transformed lymphocytes23.65
- Artery - Aorta23.62
- Skin - Sun Exposed (Lower leg)23.39
- Brain - Cerebellum23.28
- Breast - Mammary Tissue23.03
- Esophagus - Gastroesophageal Junction22.95
- Artery - Coronary22.83
- Skin - Not Sun Exposed (Suprapubic)22.76
- Pituitary22.53
And 29 more, listed on the interactive page.
- GO:0007399
- GO:0018108
- GO:0031452
- GO:0033120
- GO:1902003
- GO:1902996
- GO:2000781
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005856
- GO:0016607
- GO:0004672
- GO:0004674
- GO:0004713
- GO:0004715
- GO:0005515
- GO:0008353
- GO:0048156
- GO:0106310
- GO:0140857
regulation of catalytic activity
Studies
- biochemical: NVS_ENZ_hDYRK1a, is one of one assay component(s) measured or calculated from the NVS_ENZ_hDYRK1a assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence and electrophoretic mobility shift technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (395)
- "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "
- 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
- A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
- A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
- A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the Knee
- A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
- A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia
- A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- A Phase 1/2a Study of K-1728 in Advanced Solid Tumors
- A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
- A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer
- A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
Drugs (5)
- Cirtuvivint
- Epigalocatechin gallate
- Harmine
- Lorecivivint Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor
- Palbociclib